Mainz Biomed N.V.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $30.7M
- Price
- $1.32
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.04%
- Volume
- 1.5M
Quote data as of 7:06 AM ET
About
Mainz Biomed N.V. is a specialized enterprise in the field of molecular genetics, primarily focused on cancer diagnostics. The company's core mission involves developing and producing market-ready molecular genetic diagnostic solutions specifically engineered for life-threatening medical conditions. Beyond creation, it actively engages in the global commercialization of its product portfolio, reaching markets across Europe, the United States, and other international territories. This firm was established on March 8, 2021, and maintains its headquarters in Mainz, Germany.
Quick stats
Shares outstanding22.8M
Computed float11.4M
Float sourceUnknown
Cash runway (months)11.5
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryMedical - Diagnostics & Research
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001874252
Websitehttp://mainzbiomed.com
AI Summary
AI-generated23h agominorneutraloperations updateQuantum Cyber Completes Confidential Submission to U.S. Army Program
Quantum Cyber submitted a confidential concept white paper and technical demo video to a competitive U.S. Army technology program.
The program involves a multi-phase down-select process for dual-use autonomous capabilities, with the program's identity currently undisclosed.
Management noted the submission aligns with its strategy of engaging U.S. defense stakeholders but provided no financial details or assurance of selection.